BEST Inc. (NYSE:BEST) (“BEST” or the “Company”), a leading integrated smart supply chain solutions and logistics services provider in China and Southeast Asia, today announced that its board of directors has authorized a share repurchase program, under which BEST may repurchase up to US$20 million worth of its outstanding American Depositary Shares (“ADSs”) over the next 12 months.
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.
